The SELECT Trial: How Semaglutide Became the First Weight Loss Drug to Prevent Heart Attacks

When Maria's cardiologist suggested she consider a weight loss medication to protect her heart, she was skeptical. She'd lived with obesity for twenty years and had tried countless diets. But her doctor wasn't talking about dropping dress sizes—he was talking about preventing her second heart attack. He mentioned a study called SELECT that had just changed everything doctors thought they knew about weight loss medications and cardiovascular disease. Within months of starting semaglutide, Maria had lost 32 pounds. More importantly, she'd joined the ranks of thousands of patients benefiting from what may be the most significant cardiovascular prevention breakthrough in decades.

The SELECT trial wasn't just another weight loss study. It was specifically designed to answer a critical question: Can semaglutide actually prevent heart attacks, strokes, and cardiovascular death in high-risk patients? The answer turned out to be a resounding yes, and it's fundamentally reshaping how we think about treating both obesity and heart disease.

What Made the SELECT Trial Different From Other GLP-1 Studies

You've probably heard about the STEP trials, which demonstrated semaglutide's impressive weight loss results—up to 15% body weight reduction over 68 weeks. Those studies changed the obesity treatment landscape. But SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was designed with a completely different primary endpoint in mind.

This wasn't about weight loss at all, at least not primarily. SELECT enrolled 17,604 adults aged 45 and older who had established cardiovascular disease—meaning they'd already experienced a heart attack, stroke, or had symptomatic peripheral artery disease—plus overweight or obesity (BMI of 27 or higher), but who did not have diabetes. That last part is crucial. Previous cardiovascular outcome trials with GLP-1 medications had focused on people with type 2 diabetes, where we already knew these drugs provided heart benefits.

SELECT asked whether semaglutide could prevent major adverse cardiovascular events (MACE) in people whose only metabolic condition was excess weight. The trial ran for an average of 40 months—more than three years—making it one of the longest cardiovascular outcome studies ever conducted with a weight loss medication. Participants received either weekly injections of semaglutide 2.4 mg (the same dose used for weight management) or placebo, on top of standard cardiovascular care including medications like statins, blood pressure drugs, and antiplatelet therapy.

The study was massive in scope, enrolling patients across 41 countries and 804 clinical sites. It was also event-driven, meaning researchers didn't stop the trial until a predetermined number of cardiovascular events had occurred. This rigorous design meant the results would be definitive, not preliminary or suggestive. When the data was finally unblinded in 2023 and published in the New England Journal of Medicine, the cardiovascular community took notice immediately.

The Groundbreaking Results That Changed Cardiovascular Prevention

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events among participants taking semaglutide compared to placebo. Let that sink in for a moment. A weight loss medication reduced the risk of heart attack, stroke, and cardiovascular death by one-fifth in high-risk patients.

Breaking down the specific outcomes makes the results even more compelling. Semaglutide reduced the risk of cardiovascular death by 15%, non-fatal heart attack by 28%, and non-fatal stroke by 7%. The composite endpoint of MACE occurred in 6.5% of patients in the semaglutide group versus 8.0% in the placebo group over the trial period. These benefits appeared early—the curves separating the treatment groups began diverging within the first year—and continued to widen throughout the study duration.

Participants taking semaglutide lost an average of 9.4% of their body weight, compared to 0.9% with placebo. But here's where things get really interesting: the cardiovascular benefits appeared to exceed what you'd predict from weight loss alone. Statistical analyses suggested that only about 25% of the cardiovascular benefit could be explained by the weight reduction. The remaining 75% seemed to come from other mechanisms—improvements in inflammation, blood pressure, lipids, and possibly direct effects on the cardiovascular system itself.

We see this frequently in our patients who start GLP-1 therapy. Their blood pressure improves before significant weight loss occurs. Their inflammatory markers drop. Their triglycerides come down. Semaglutide appears to be doing something beyond simple calorie restriction, and SELECT provided the long-term outcome data to prove those biological changes translate into fewer heart attacks and strokes.

The safety profile in SELECT mirrored what we'd seen in previous semaglutide trials. Gastrointestinal side effects like nausea and diarrhea were the most common, typically mild to moderate and improving over time. Serious adverse events occurred at similar rates in both groups, and importantly, there were no unexpected safety signals despite the large sample size and extended duration.

Why These Findings Matter for Patients With Heart Disease and Obesity

Before SELECT, the conversation around obesity and cardiovascular disease focused primarily on risk factors. We knew excess weight increased blood pressure, worsened cholesterol, promoted inflammation, and raised diabetes risk. Treating obesity made theoretical sense for heart protection, but we lacked definitive proof that weight loss medications specifically could prevent cardiovascular events in this population.

SELECT changed that calculation entirely. Now we have Level A evidence—the highest quality clinical data—that semaglutide prevents heart attacks and strokes in people with established cardiovascular disease and overweight or obesity. This isn't about looking better or fitting into smaller clothes (though those can be welcome side effects). This is about preventing premature death and disability from the leading cause of mortality worldwide.

The implications extend to how we classify and prescribe these medications. Following SELECT's publication, the FDA approved a new indication for semaglutide: reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. This marked the first time any weight management medication had received an indication for cardiovascular risk reduction. Semaglutide wasn't just a weight loss drug anymore—it was a cardiovascular prevention therapy.

For patients, this shifts the entire framework of the conversation. If you've had a heart attack or stroke, or if you have significant cardiovascular disease, and you're carrying excess weight, semaglutide isn't optional lifestyle management—it's potentially lifesaving medical treatment. It belongs in the same conversation as statins, beta-blockers, and ACE inhibitors. Insurance companies are beginning to recognize this distinction, with some plans now covering GLP-1 medications when prescribed specifically for cardiovascular risk reduction in SELECT-eligible patients, even if they previously denied coverage for weight management.

The trial also validated what many clinicians had suspected: obesity itself is a cardiovascular disease risk factor that deserves direct pharmacological treatment, not just lifestyle counseling. For too long, patients with heart disease and obesity heard 'just lose weight' without being offered effective tools to do so. SELECT demonstrated that we now have a medication that treats both conditions simultaneously.

How SELECT Compares to Other Cardiovascular Outcome Trials

SELECT didn't happen in a vacuum. It built upon a foundation of cardiovascular outcome trials with GLP-1 receptor agonists in people with type 2 diabetes. The LEADER trial with liraglutide, SUSTAIN-6 with once-weekly semaglutide, and REWIND with dulaglutide all showed cardiovascular benefits in diabetic populations. But those patients had multiple metabolic abnormalities—elevated blood sugar, insulin resistance, often diabetic kidney disease—making it difficult to isolate the specific contribution of the GLP-1 medication versus improved glucose control.

SELECT's stroke of genius was studying people without diabetes. These participants had relatively normal blood sugar levels at baseline. Their cardiovascular risk came primarily from their weight, hypertension, dyslipidemia, and history of vascular events. By demonstrating benefit in this population, SELECT proved that semaglutide's cardiovascular protection extends beyond glucose lowering. It works through multiple pathways that remain active even when blood sugar is normal.

The 20% MACE reduction in SELECT compares favorably to other established cardiovascular therapies. High-intensity statin therapy reduces cardiovascular events by about 25-30%. SGLT2 inhibitors, another newer drug class, reduce cardiovascular death and hospitalization for heart failure by roughly 20-25% in heart failure patients. Semaglutide's effect size puts it in the same league as these proven therapies, which is remarkable for a medication that wasn't originally developed as a heart drug.

What's still unknown is how semaglutide performs compared to tirzepatide, the dual GIP/GLP-1 receptor agonist that's shown even greater weight loss in head-to-head studies. The SURMOUNT-1 trial demonstrated that tirzepatide produces up to 22.5% weight reduction—substantially more than semaglutide's 15%. A cardiovascular outcome trial with tirzepatide (SURMOUNT-MMO) is currently underway, enrolling patients with obesity and cardiovascular disease similar to SELECT's population. Results aren't expected until 2025 or beyond, but many researchers anticipate that tirzepatide's greater metabolic impact might translate to even larger cardiovascular benefits.

What Women Should Know About SELECT and Cardiovascular Protection

Heart disease remains the leading cause of death for women, yet cardiovascular research has historically underrepresented female participants. SELECT bucked that trend—approximately 28% of participants were women, providing robust data on sex-specific effects. The cardiovascular benefits of semaglutide appeared consistent across sexes, meaning women experienced similar relative risk reductions as men.

This matters because women's cardiovascular disease often presents differently than men's. Women are more likely to have microvascular disease, diffuse plaque, and atypical symptoms. They're also more likely to be dismissed or have their symptoms attributed to anxiety rather than cardiac causes. Having clear evidence that semaglutide works for cardiovascular protection in women gives both patients and providers another tool for prevention, particularly in the years following menopause when cardiovascular risk accelerates rapidly.

Women should also know that pregnancy is a contraindication to semaglutide use. If you're of childbearing age and sexually active, reliable contraception is essential while taking this medication, and you should discontinue it at least two months before attempting to conceive. The cardiovascular benefits are long-term, but protecting a potential pregnancy takes immediate priority.

What Men Should Know About Cardiovascular Risk and GLP-1 Therapy

Men develop cardiovascular disease earlier than women on average, often experiencing their first heart attack in their 50s or even 40s. If you're a man with a history of cardiovascular events and you're carrying extra weight—particularly visceral abdominal fat, which is more metabolically harmful—SELECT's findings are directly relevant to your long-term survival.

The 28% reduction in non-fatal heart attacks seen in SELECT is particularly significant for men, who experience heart attacks at higher rates than women until advanced age. If you've already had one cardiac event, your risk of a second is substantially elevated. Adding semaglutide to your prevention regimen—alongside the medications you're likely already taking—could meaningfully lower that risk.

Men should also be aware that cardiovascular disease and erectile dysfunction often share common causes: endothelial dysfunction, atherosclerosis, and metabolic syndrome. While SELECT didn't specifically study erectile function, some men in our practice report improvements in this area with weight loss and metabolic optimization. It's not guaranteed, but it reflects the interconnected nature of vascular health throughout the body.

From the Ozari Care Team

We recommend discussing SELECT with your healthcare provider if you have any history of cardiovascular disease—heart attack, stroke, coronary artery disease, or peripheral artery disease—combined with a BMI of 27 or higher. The trial's results suggest you might benefit from semaglutide not just for weight management, but for genuine heart attack and stroke prevention. In our experience, patients who understand they're taking a medication for cardiovascular protection rather than just weight loss often have better adherence and more realistic expectations about the timeline for benefits. What we tell our patients is that this represents a fundamental shift in how we approach obesity treatment—from cosmetic concern to cardiovascular risk management—and SELECT provided the evidence to support that change.

Key Takeaways

• The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in people with established heart disease and overweight or obesity, even without diabetes
• Cardiovascular benefits appear within the first year of treatment and include a 28% reduction in non-fatal heart attacks and 15% reduction in cardiovascular death
• Only about 25% of the cardiovascular benefit comes from weight loss itself—the remaining 75% appears related to improvements in inflammation, blood pressure, lipids, and direct vascular effects
• Following SELECT, semaglutide became the first weight management medication approved by the FDA specifically for reducing cardiovascular risk in high-risk patients
• The trial enrolled over 17,600 patients across 41 countries for an average of 40 months, making it one of the largest and longest cardiovascular outcome studies ever conducted with a weight loss medication

Frequently Asked Questions

Do I qualify for semaglutide based on SELECT trial criteria?

You'd meet SELECT criteria if you're 45 or older with a BMI of 27 or higher and established cardiovascular disease—meaning you've had a previous heart attack, stroke, or symptomatic peripheral artery disease. Importantly, SELECT participants did not have diabetes, so these results specifically apply to people whose primary metabolic condition is excess weight. If you do have diabetes, that doesn't disqualify you from semaglutide; it just means your cardiovascular benefits are supported by different trials like SUSTAIN-6 rather than SELECT. Talk with your provider about your specific cardiovascular and metabolic history to determine if this medication is appropriate for you.

How long does it take to see cardiovascular benefits from semaglutide?

The survival curves in SELECT started separating within the first 12 months of treatment, suggesting cardiovascular benefits begin relatively early. However, the benefits continued to accumulate over the full 40-month average follow-up period, meaning longer treatment duration provided greater protection. This isn't a quick fix—it's a long-term preventive therapy similar to taking a statin or blood pressure medication. We typically tell patients to think of this as an ongoing commitment to cardiovascular protection, not a temporary intervention. The weight loss happens more quickly (most occurs in the first 6-12 months), but the cardiovascular benefits build over years.

Will insurance cover semaglutide for cardiovascular protection?

Coverage is evolving following SELECT's publication and the FDA's approval of the cardiovascular indication. Some insurance plans now cover semaglutide when prescribed specifically for cardiovascular risk reduction in patients who meet SELECT criteria, even if they previously denied coverage for weight management alone. Medicare coverage remains complex—traditional Medicare Part D plans often exclude weight loss medications, but the cardiovascular indication may create coverage pathways through different mechanisms. Your best approach is to have your provider submit a prior authorization specifically citing the cardiovascular indication if you have documented heart disease. Compounded semaglutide options like those offered through Ozari Health provide an affordable alternative ($99/month) when insurance denials occur.

Can I take semaglutide if I'm already on other heart medications?

Yes, and you absolutely should continue your other cardiovascular medications. SELECT participants were already on standard guideline-directed medical therapy—93% were taking antiplatelet drugs like aspirin, 90% were on statins, 83% were taking ACE inhibitors or ARBs for blood pressure, and 76% were on beta-blockers. Semaglutide was added on top of these medications, not instead of them. Think of it as another tool in your cardiovascular protection toolkit, working through different mechanisms than your other drugs. The combination is what provides optimal protection. Never stop existing heart medications to start semaglutide—this medication adds to your regimen, it doesn't replace proven therapies.

What's the difference between the SELECT trial and the STEP weight loss trials?

The STEP trials studied semaglutide primarily for weight loss in people with obesity, measuring outcomes like percentage body weight reduction and improvements in obesity-related complications. SELECT used the same semaglutide dose (2.4 mg weekly) but studied a different population—people with established cardiovascular disease—and measured different outcomes: heart attacks, strokes, and cardiovascular death. While STEP participants lost slightly more weight on average (about 15% versus 9.4% in SELECT), SELECT's participants were older, had more medical comorbidities, and were specifically selected for high cardiovascular risk. The trials complement each other: STEP proved semaglutide's weight loss efficacy, while SELECT proved it prevents cardiovascular events. Both matter, but SELECT elevated semaglutide from a lifestyle medication to a potentially lifesaving cardiovascular therapy.

At Ozari Health, we offer compounded Semaglutide and Tirzepatide as low as $99/month, shipped to your door. Learn more at ozarihealth.com.